Researchers took blood samples from 106 COVID-19 patients at three, six and 12 months after a diagnosis and compared them to control patients.
Forty-one percent of the COVID-19 patients had autoantibodies in their blood. Around 20 percent to 30 percent of the patients, many of whom had lingering symptoms, had inflammation markers in their blood and two types of autoantibodies with known links to autoimmune diseases.
“There will be a subset of patients who will end up with a diagnosis for life,” Manali Mukherjee, PhD, the study’s senior author and an assistant professor of medicine at McMaster University in Hamilton, Ontario, told NBC News Sept. 27.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
